At the 2026 Annual Meeting of the European Society of Medical Oncology held from October 23 to 27, China's innovative drugs ushered in a “highlight moment”: 29 innovative Chinese drug studies were selected for breakthrough summaries, accounting for about one-third of the total LBA of the conference, a record high; among them, 5 studies ranked among the highest-standard presidential seminars at the conference, achieving double breakthroughs in quantity and quality. Industry experts believe that this year's ESMO has once again confirmed the differentiated innovation advantages of China's innovative drugs. At the same time, China's innovative drugs are ushering in a critical transition from “early efficacy display” to “global phase III clinical verification”, showing a leap in the maturity of the industry.

At the 2026 Annual Meeting of the European Society of Medical Oncology held from October 23 to 27, China's innovative drugs ushered in a “highlight moment”: 29 innovative Chinese drug studies were selected for breakthrough summaries, accounting for about one-third of the total LBA of the conference, a record high; among them, 5 studies ranked among the highest-standard presidential seminars at the conference, achieving double breakthroughs in quantity and quality. Industry experts believe that this year's ESMO has once again confirmed the differentiated innovation advantages of China's innovative drugs. At the same time, China's innovative drugs are ushering in a critical transition from “early efficacy display” to “global phase III clinical verification”, showing a leap in the maturity of the industry.